IDEXX Laboratories (IDXX)
(Delayed Data from NSDQ)
$510.19 USD
+9.37 (1.87%)
Updated May 10, 2024 03:59 PM ET
After-Market: $510.36 +0.17 (0.03%) 4:42 PM ET
4-Sell of 5 4
D Value A Growth F Momentum C VGM
Price, Consensus and EPS Surprise
IDXX 510.19 +9.37(1.87%)
Will IDXX be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for IDXX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for IDXX
IDEXX (IDXX) Q1 Earnings Surpass Estimates, 2024 View Slashed
Compared to Estimates, Idexx (IDXX) Q1 Earnings: A Look at Key Metrics
IDXX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Idexx Laboratories (IDXX) Tops Q1 Earnings Estimates
Bruker's (BRKR) Balanced Segmental Growth, Innovation Aid
Philips (PHG) Receives FDA Warning Letter Regarding CT Systems
Other News for IDXX
IDEXX Laboratories Sees Leadership Transition and Shareholder Approval
Baron Small Cap Fund Q1 2024 Shareholder Letter
Idexx Laboratories Breaks Above 200-Day Moving Average - Bullish for IDXX
Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN), Idexx Laboratories (IDXX) and ImmunityBio (IBRX)
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Owens & Minor (OMI), Idexx Laboratories (IDXX) and CytomX Therapeutics (CTMX)